Dr Sharman summarises his experience of the outcome of an open label, phase 1b/2 trial on 31 previously untreated patients (29 with CLL and 2 with SLL) between 65 and 84 years old (average age 71) that required therapy.
After a median follow-up of 22·1 months, 71% of 31 patients achieved an objective response, 13% had a complete response, one patient (3%) had a nodular partial response, and 17 (55%) patients had a partial response.
For the complete summary, which includes side effects experienced and their severity,
cll-nhl.com/2013/12/ibrutin...
This was termed a phase 1b/2 trial because "Patients received 28 day cycles of once-daily ibrutinib 420 mg or ibrutinib 840 mg. The 840 mg dose was discontinued after enrolment had begun because comparable activity of the doses has been shown." i.e. the appropriate dosage was still being determined initially.
healthunlocked.com/cllsuppo...
Open label means both the researchers and participants know which treatment is being administered.
Neil
Today's photo shows some galahs (rose-breasted cockatoos) feeding in a local park. If an Australian calls you a galah or perhaps a silly galah, it's generally not a complimentary term:
australiandictionary.net/galah
John Williamson (an Australian Country singer-songwriter) uses the phrase in his first hit from 1970 'Old Man Emu'. John is old enough to qualify for the above Ibrutinib trial (not that he has CLL to my knowledge) and I respect his decision to keep his Aussie accent despite the pressures to lose it to further his singing career overseas.
Have a listen if you'd like to hear a fun song by someone with a genuine Aussie accent:
ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters
